Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adèle Thomas

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
BMC Women'S Health|September 15, 2020
Women's views about physical activity as a treatment for vasomotor menopausal symptoms: a qualitative studyAdèle Thomas, Amanda J Daley
Methods in Molecular Medicine|March 2, 2006
The bioassay of cannabinoids using the mouse isolated vas deferensAdèle Thomas, Roger G Pertwee
The Cochrane Database of Systematic Reviews|November 29, 2014
Exercise for vasomotor menopausal symptomsAmanda Daley, Helen Stokes-Lampard, Adèle Thomas, et al.
European Journal of Pharmacology|November 27, 2002
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferensRoger G Pertwee, Ruth A Ross, Susan J Craib, et al.
Neuropharmacology|May 25, 2005
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferensRoger G Pertwee, Adèle Thomas, Lesley A Stevenson, et al.
European Journal of Pharmacology|March 23, 2004
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonistAdèle Thomas, Ruth A Ross, Bijali Saha, et al.
Maturitas|September 28, 2013
Aerobic exercise as a treatment for vasomotor menopausal symptoms: randomised controlled trial protocolAmanda J Daley, Helen Stokes-Lampard, Adèle Thomas, et al.
British Journal of Pharmacology|October 6, 2005
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistAdèle Thomas, Lesley A Stevenson, Kerrie N Wease, et al.
FEBS Letters|January 13, 2006
First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligandsGiovanni Appendino, Maria Grazia Cascio, Sara Bacchiega, et al.
Molecular Pharmacology|August 23, 2005
Allosteric modulation of the cannabinoid CB1 receptorMartin R Price, Gemma L Baillie, Adèle Thomas, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
BMC Women'S Health|September 15, 2020
Women's views about physical activity as a treatment for vasomotor menopausal symptoms: a qualitative studyAdèle Thomas, Amanda J Daley
Methods in Molecular Medicine|March 2, 2006
The bioassay of cannabinoids using the mouse isolated vas deferensAdèle Thomas, Roger G Pertwee
The Cochrane Database of Systematic Reviews|November 29, 2014
Exercise for vasomotor menopausal symptomsAmanda Daley, Helen Stokes-Lampard, Adèle Thomas, et al.
European Journal of Pharmacology|November 27, 2002
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferensRoger G Pertwee, Ruth A Ross, Susan J Craib, et al.
Neuropharmacology|May 25, 2005
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferensRoger G Pertwee, Adèle Thomas, Lesley A Stevenson, et al.
European Journal of Pharmacology|March 23, 2004
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonistAdèle Thomas, Ruth A Ross, Bijali Saha, et al.
Maturitas|September 28, 2013
Aerobic exercise as a treatment for vasomotor menopausal symptoms: randomised controlled trial protocolAmanda J Daley, Helen Stokes-Lampard, Adèle Thomas, et al.
British Journal of Pharmacology|October 6, 2005
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonistAdèle Thomas, Lesley A Stevenson, Kerrie N Wease, et al.
FEBS Letters|January 13, 2006
First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligandsGiovanni Appendino, Maria Grazia Cascio, Sara Bacchiega, et al.
Molecular Pharmacology|August 23, 2005
Allosteric modulation of the cannabinoid CB1 receptorMartin R Price, Gemma L Baillie, Adèle Thomas, et al.
Pageof 1